Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS discontinues one Masters programme
2006-07-26

As from next year, the University of the Free State (UFS) will no longer offer one of its specialist master’s degrees in education – the M Ed in Education Management.

 The other six M Ed programmes that are currently being offered at the UFS will continue as normal.

 The decision to discontinue one of the M Ed programmes follows a national review of M Ed programmes in Educational Management and Leadership by the Higher Education Quality Committee (HEQC) of the Council on Higher Education (CHE).

 Of the 23 tertiary institutions whose M Ed programmes in Educational Management and Leadership were reviewed by the HEQC, only 7 received full accreditation.   

 “The findings of the HEQC affect only one of our M Ed degree programmes, namely the M Ed in Educational Management,” said Prof Magda Fourie, Vice-Rector: Academic Planning at the UFS

 “We will be paying full attention to the findings of the HEQC with a view to correcting some of the shortcomings that have been identified by the HEQC and will consider submitting a reviewed proposal for such a qualification in two years time,” she said.

 According to Prof Fourie, the programme currently has 30 students enrolled.  “These students – spread across their first and second years of the degree programme – will be allowed to complete their studies with the full support of the UFS and the School of Education,” said Prof Fourie.

 “The qualification that has been awarded to students who have already completed their studies for this specific M Ed in Education Management degree programme remains a valid qualification and is not affected by the HEQC review,” said Prof Fourie.

 She said the UFS welcomed the efforts of the HEQC to ensure that all academic programmes offered by higher education institutions meet certain standards.

“One of the primary problem areas in the M Ed in Educational Management offered by the UFS identified by the HEQC, was that the programme is too practice orientated and must be more theoretical to comply with the academic requirements of a master’s degree.  This was a result of the fact that the programme was initially compiled in consultation with principals and the provincial Department of Education to address their needs,” said Prof Fourie.

“The UFS will in the mean time offer an advanced certificate in Educational Management and Leadership from next year.  This is a new course that will stretch over a period of two years and will ensure that we can still address the needs of teachers and principals,” said Prof Fourie.

 “The UFS remains committed to providing top quality degree programmes in all its six faculties and will continue to work with the HEQC in ensuring that this actually happens,” said Prof Fourie.

Media release
Issued by: Lacea Loader
Media Representative
Tel:   (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za 
25 July 2006

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept